Defilade Capital Management, L.P. holds a focused book of 31 stocks worth $712.2M as of Q1 2026 (disclosed Jun 12, 2026, a ~73-day 13F lag). This quarter they opened Zimmer Biomet Holdings Inc and trimmed Pfizer Inc. Their largest long position is Zimmer Biomet Holdings Inc at 7% of the equity book. Cloning the disclosed picks since 2026 would be +3% (+6.5%/yr). That is a simulation of the disclosed long book, not audited returns.
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/2088557/holdings"
Use Arkolith to show Defilade Capital Management, L.P.'s latest holdings, largest changes, and filing provenance.
Growth of $10,000 cloning Defilade Capital Management, L.P.'s disclosed long 13F book, rebalanced on each filing date (so it reflects each quarter's actual reporting lag, ~73 days for the latest filing, with no look-ahead), total-return basis (dividends reinvested), derived from end-of-day prices. “Their reported book” values the same picks from quarter-end, before they were public. S&P 500 is SPY total return over the same window. Excludes shorts, cash, options and non-13F holdings. Not investment advice.
Top-heavy: focused book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
98% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices, no cost basis
Other tracked managers holding the same core names as Defilade Capital Management, L.P.
| Manager / fund | Shared names | Their $ in those |
|---|---|---|
| BlackRock, Inc. | 42 / 31 | $151.2B |
| STATE STREET CORP | 42 / 31 | $78.6B |
| JPMORGAN CHASE & CO | 42 / 31 | $34.7B |
| MORGAN STANLEY | 42 / 31 | $33.6B |
| BANK OF AMERICA CORP /DE/ | 42 / 31 | $21.7B |
| UBS Group AG | 42 / 31 | $11.1B |
| WELLS FARGO & COMPANY/MN | 42 / 31 | $8.0B |
| BARCLAYS PLC | 42 / 31 | $4.5B |
Ranked by how many of Defilade Capital Management, L.P.'s top 31 disclosed names each fund also holds: a cross-fund conviction signal from the latest 13F of every tracked manager.
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Zimmer Biomet Holdings Inc COM | $52.4M | 579.2K | 7.4% | ▲New New position | |
| 2 | Schein Henry Inc COM | $46.0M | 624.0K | 6.5% | ▲+95% Added · +304K sh | |
| 3 | Becton Dickinson & Co COM | $43.9M | 279.2K | 6.2% | ▲+244% Added · +198K sh | |
| 4 | Pfizer Inc COM | $41.1M | 1.46M | 5.8% | ▼−34% Reduced · −739K sh | |
| 5 | Dexcom Inc COM | $33.8M | 538.8K | 4.8% | ▲+120% Added · +294K sh | |
| 6 | Icu Med Inc COM | $32.8M | 254.3K | 4.6% | ▼−25% Reduced · −86K sh | |
| 7 | Insmed Inc COM PAR $.01 | $31.9M | 194.9K | 4.5% | ▲+290% Added · +145K sh | |
| 8 | Intuitive Surgical Inc COM NEW | $31.2M | 67.7K | 4.4% | ▲+48% Added · +22K sh | |
| 9 | Revolution Medicines Inc COM | $30.7M | 316.0K | 4.3% | ▼−13% Reduced · −47K sh | |
| 10 | Globus Med Inc CL A | $30.5M | 354.4K | 4.3% | ▲+33% Added · +87K sh | |
| 11 | Neurocrine Biosciences Inc COM | $27.7M | 209.9K | 3.9% | ▲New New position | |
| 12 | Denali Therapeutics Inc COM | $26.1M | 1.36M | 3.7% | ▲+107% Added · +703K sh | |
| 13 | PTC Therapeutics Inc COM | $25.6M | 376.2K | 3.6% | ▲New New position | |
| 14 | Olema Pharmaceuticals Inc COM | $22.4M | 1.50M | 3.1% | ▲+22% Added · +270K sh | |
| 15 | Elanco Animal Health Inc COM | $22.3M | 931.1K | 3.1% | ▲+132% Added · +530K sh | |
| 16 | Pacs Group Inc COM SHS | $19.4M | 604.2K | 2.7% | ▼−47% Reduced · −541K sh | |
| 17 | Eli Lilly & Co COM | $19.0M | 20.7K | 2.7% | ▼−35% Reduced · −11K sh | |
| 18 | Lantheus Hldgs Inc COM | $18.9M | 249.4K | 2.7% | ▲New New position | |
| 19 | Integer Hldgs Corp COM | $18.7M | 213.0K | 2.6% | ▲New New position | |
| 20 | Biogen Inc COM | $17.7M | 96.3K | 2.5% | ▼−41% Reduced · −66K sh | |
| 21 | Evommune Inc COM SHS | $15.6M | 678.6K | 2.2% | ▲+215% Added · +463K sh | |
| 22 | Tandem Diabetes Care Inc COM NEW | $14.6M | 761.9K | 2.1% | ▲New New position | |
| 23 | Cogent Biosciences Inc COM | $13.6M | 352.6K | 1.9% | ▼−38% Reduced · −216K sh | |
| 24 | Nuvalent Inc COM | $13.3M | 129.9K | 1.9% | ▼−52% Reduced · −139K sh | |
| 25 | Ocular Therapeutix Inc COM | $12.6M | 1.49M | 1.8% | ▲+118% Added · +806K sh | |
| 26 | Ascendis Pharma A/s SPONSORED ADR | $11.9M | 51.9K | 1.7% | ▼−39% Reduced · −34K sh | |
| 27 | Align Technology Inc COM | $11.5M | 67.3K | 1.6% | ▼−47% Reduced · −61K sh | |
| 28 | Eledon Pharmaceuticals Inc COM | $11.0M | 3.56M | 1.5% | ▲+8.3% Added · +274K sh | |
| 29 | Oric Pharmaceuticals Inc COM | $10.7M | 842.9K | 1.5% | ▲New New position | |
| 30 | Biohaven Ltd COM | $2.7M | 315.9K | 0.4% | ▲New New position | |
| 31 | Mereo Biopharma Group PLC SPON ADS | $2.5M | 7.56M | 0.4% | ▲New New position |
As-of date vs the date the SEC received each filing
| Quarter | As of | Filed | Positions | Value | Form |
|---|---|---|---|---|---|
| Q1 2026 | Mar 31, 2026 | Jun 12, 2026 | 31 | $712.2M | 13F-HR/A |
| Q4 2025 | Dec 31, 2025 | Feb 13, 2026 | 33 | $737.7M | 13F-HR |
Holdings from SEC EDGAR 13F-HR filings, updated quarterly, filed up to 45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. The performance line is a simulation of the disclosed long book, not an audited return.